Economic headwinds and recessionary fears will not slow down healthcare dealmaking next year coming off a robust M&A market in 2022.
Increasing transaction volumes and players embracing value-based care—coupled with large levels of corporate cash and private equity “dry powder”—are leading to continued expansion for deal volumes in 2023, according to a new analysis from PwC, Fierce Healthcare reports.
The accounting and consulting firm forecasts a strong outlook for health services M&A deals in 2023 with companies actively exploring M&A, divestitures and other transactions, said Nick Donkar, PwC’s U.S. health services deals leader.
“The deal market in 2022 was fairly robust coming off an unprecedented banner year, which was 2021. Obviously, 2021 was the highest deal volume we’ve experienced from a health services perspective. We’re happy to see the health of the overall market, no pun intended, with respect to the level of volume and activity that has been exhibited thus far in 2022,” he said. Read more.
